The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin—The Sit2Mix trial

Autor: Radhakrishna Sothiratnam, Sultan Linjawi, Paturi Rao, Line Conradsen Hiort, Ramazan Sari, Henning F. Andersen
Jazyk: angličtina
Předmět:
Blood Glucose
Male
Time Factors
Sitagliptin Phosphate/administration & dosage
Endocrinology
Diabetes and Metabolism
Cost-Benefit Analysis
Insulin
Isophane
Biphasic Insulins/administration & dosage
Type 2 diabetes
law.invention
Metformin/administration & dosage
Randomized controlled trial
law
Biphasic insulin
Nutrition and Dietetics
Middle Aged
Metformin
Europe
Treatment Outcome
Tolerability
Sitagliptin
Drug Therapy
Combination
Female
Randomized trial
Family Practice
Diabetes Mellitus
Type 2/blood
medicine.drug
medicine.medical_specialty
Asia
Glycated Hemoglobin A/metabolism
Biphasic Insulins
Drug Administration Schedule
Drug Costs
Insulin
Isophane/administration & dosage
Blood Glucose/drug effects
Diabetes mellitus
Internal medicine
Internal Medicine
medicine
Hypoglycemic Agents
Humans
In patient
Insulin Aspart/administration & dosage
Insulin Aspart
Aged
Glycated Hemoglobin
business.industry
Sitagliptin Phosphate
Australia
South America
medicine.disease
Hypoglycemic Agents/administration & dosage
Biphasic insulin aspart
Endocrinology
Diabetes Mellitus
Type 2
business
Biomarkers
Biomarkers/blood
Zdroj: Linjawi, S, Sothiratnam, R, Sari, R, Andersen, H, Hiort, L C & Rao, P 2015, ' The study of once-and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial ', Primary care diabetes, vol. 9, no. 5, pp. 370-6 . https://doi.org/10.1016/j.pcd.2014.11.001
ISSN: 1751-9918
DOI: 10.1016/j.pcd.2014.11.001
Popis: AIMS: Investigate efficacy and tolerability of intensifying diabetes treatment with once- or twice-daily biphasic insulin aspart 30 (BIAsp 30) added to sitagliptin, and twice-daily BIAsp 30 without sitagliptin in patients with type 2 diabetes (T2D) inadequately controlled on sitagliptin.METHODS: Open-label, three-arm, 24-week trial; 582 insulin-naïve patients were randomized to twice-daily BIAsp 30+sitagliptin (BIAsp BID+Sit), once-daily BIAsp 30+sitagliptin (BIAsp QD+Sit) or twice-daily BIAsp 30 without sitagliptin (BIAsp BID), all with metformin.RESULTS: After 24 weeks, HbA1c reduction (%) was superior with BIAsp BID+Sit vs. BIAsp QD+Sit (BIAsp BID+Sit minus BIAsp QD+Sit difference: -0.36 [95% CI -0.54; -0.17], PCONCLUSIONS: Adding BIAsp 30 to patients with T2D poorly controlled with sitagliptin and metformin is efficacious and well tolerated; however, while BIAsp BID+Sit showed superior glycaemic control, BIAsp QD+Sit had a lower rate of hypoglycaemia and showed no weight gain.
Databáze: OpenAIRE
Externí odkaz: